Author(s): Samuel Deshayes, Mehdi Khellaf, Anissa Zarour, et al. Abstract: S141 Session topic: 33. Platelets disorders Background The long-term safety and efficacy of rituximab (RTX) in adult’s immune thrombocytopenia (ITP) are not well known and current data are only based on retrospective studies. Aims To assess long-term (5 to 7 years...
Pro zobrazení tohoto obsahu je třeba být přihlášen.